systemic-sclerosis
(2)
Mediar Therapeutics wants to stop the scar makers
Three hospital research programs became one biotech with a shared suspicion: fibrosis might be interrupted where scar tissue is made. Now Mediar is testing that idea in lungs, skin and kidneys - with Lilly and Ono taking an interest.
Prolium Bioscience
Prolium Bioscience is a New York-based, clinical-stage biotechnology company developing PRO-203, a bispecific CD20xCD3 T-cell engager designed to deplete disease-driving B cells as an off-the-shelf therapy for severe autoimmune diseases, starting with systemic sclerosis and lupus. Founded in 2025 and backed by RTW Investments, the company in-licensed global non-oncology and ex-Asia oncology rights to the antibody from China's InnoCare Pharma and KeyMed Biosciences, and launched publicly in March 2026 with a $50 million Series A alongside first-patient dosing.